Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to treating many types of cancer. However, it doesn't work well for some tumors, ...

Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

Today, AbbVie has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be ...

Award-winning journalist Christiane Amanpour has revealed that her ovarian cancer has returned for the third time, saying she is under immunotherapy for treatment. Amanpour, who was first diagnosed in ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1b/2 ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has announced a new clinical study titled A Randomised, ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...